James HesterBayer, the German-listed pharmaceutical group, said it had failed to meet the objectives of clinical trials for its pneumonia drug Amikacin Inhale.
Shares were down by around 0.5% in early trading on Friday.
Amikacin Inhale disappointed expectations and did not exhibit superiority over a placebo in phase 3 clinical trials. The drug failed to meet both the primary and secondary objectives of the study.
Amikacin Inhale combines a version of the antibiotic amikacin with an inhalation system pioneered by Nektar Therapeutics to deliver the drug to patients’ lungs.
Bayer has been developing the Amikacin Inhale programme in partnership with Nektar.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.
